

Product datasheet for TF311980

KIAA0100 Human shRNA Plasmid Kit (Locus ID 9703)

Product data:

Product Type:	shRNA Plasmids
Product Name:	KIAA0100 Human shRNA Plasmid Kit (Locus ID 9703)
Locus ID:	9703
Synonyms:	BCOX; BCOX1; CT101; FMP27
Vector:	pRFP-C-RS (TR30014)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	KIAA0100 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 9703). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
RefSeq:	NM_001321560 , NM_001321561 , NM_014680 , NM_014680.1 , NM_014680.2 , NM_014680.3 , BC008591 , BC048096 , BC050440 , BC103726 , BC120873 , BM999622 , NM_001363827 , NM_001363828 , NM_001363829 , NM_001363826 , NM_014680.5
UniProt ID:	Q14667
Summary:	This gene was initially characterized in human as having high expression levels in breast carcinomas and breast cancer cell lines. This gene also has increased expression in prostate cancer cells relative to normal prostate tissues. Expression of this gene is negatively regulated by direct binding of the microRNA miR-195 to its 3' UTR. miR-195 has been shown to modulate the invasiveness of prostate cancer cells and xenograft metastases by downgrading expression of this gene. In mouse, the protein encoded by this gene was identified as an antigen on acute monocytic leukemia cells. In human, alternative splicing results in multiple transcript variants encoding distinct isoforms; some of these isoforms are predicted to contain an RNA pol II promoter FMP27 protein domain and a Golgi-body-localization APT1 domain. [provided by RefSeq, Apr 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .


[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).